Premium
Adjuvant chemotherapy for large cell carcinoma with neuroendocrine features
Author(s) -
Iyoda Akira,
Hiroshima Kenzo,
Toyozaki Tetsuya,
Haga Yukiko,
Baba Masayuki,
Fujisawa Takehiko,
Ohwada Hidemi
Publication year - 2001
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(20010901)92:5<1108::aid-cncr1427>3.0.co;2-7
Subject(s) - medicine , carboplatin , chemotherapy , oncology , carcinoma , small cell carcinoma , cyclophosphamide , large cell , small cell lung carcinoma , cisplatin , neuroendocrine differentiation , adjuvant , cancer , pathology , adenocarcinoma , prostate cancer
BACKGROUND In 1999, the World Health Organization categorized large cell neuroendocrine carcinoma, large cell carcinoma with neuroendocrine differentiation, and large cell carcinoma with neuroendocrine morphology as a variant of large cell carcinoma. Patients with large cell carcinoma with neuroendocrine features have poor prognoses, comparable to those for small cell lung carcinoma. Small cell lung carcinoma is sensitive to chemotherapy; however, it is still unclear whether large cell carcinoma with neuroendocrine features is responsive to adjuvant chemotherapy. METHODS The authors analyzed 73 patients with large cell carcinoma with neuroendocrine features who underwent resection of the tumor and studied the effect of adjuvant chemotherapy for large cell carcinoma with neuroendocrine features. RESULTS In patients with Stage I disease, the overall survival for patients with adjuvant chemotherapy based on cisplatin, carboplatin, or cyclophosphamide, which were used as standard chemotherapy for small cell lung carcinoma, were significantly higher than the overall survival for patients without adjuvant chemotherapy. In patients with Stage II, III, and IV disease, there was no significant difference between patients with adjuvant chemotherapy and without adjuvant chemotherapy. CONCLUSIONS Adjuvant chemotherapy based on cisplatin, carboplatin, or cyclophosphamide prolongs survival of patients with large cell carcinoma with neuroendocrine features in early stage. Cancer 2001;92:1108–12. © 2001 American Cancer Society.